KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Gross Margin: 2017-2025

Historic Gross Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to 34.92%.

  • Amneal Pharmaceuticals' Gross Margin fell 345.00% to 34.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.76%, marking a year-over-year increase of 142.00%. This contributed to the annual value of 36.52% for FY2024, which is 224.00% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Gross Margin of 34.92% as of Q3 2025, which was down 11.61% from 39.51% recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Gross Margin high stood at 39.71% for Q2 2021, and its period low was 30.77% during Q4 2023.
  • Moreover, its 3-year median value for Gross Margin was 36.11% (2024), whereas its average is 35.84%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 1,183bps in 2021, then tumbled by 456bps in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Gross Margin (Quarterly) stood at 30.99% in 2021, then skyrocketed by 433bps to 35.32% in 2022, then crashed by 456bps to 30.77% in 2023, then skyrocketed by 522bps to 35.98% in 2024, then tumbled by 345bps to 34.92% in 2025.
  • Its Gross Margin was 34.92% in Q3 2025, compared to 39.51% in Q2 2025 and 36.80% in Q1 2025.